鲁海嘉, 张东峰, 黄海洪. 抗革兰氏阴性菌药物的研究进展J. 药学学报, 2019,54(9): 1554-1563. doi: 10.16438/j.0513-4870.2019-0467
引用本文: 鲁海嘉, 张东峰, 黄海洪. 抗革兰氏阴性菌药物的研究进展J. 药学学报, 2019,54(9): 1554-1563. doi: 10.16438/j.0513-4870.2019-0467
LU Hai-jia, ZHANG Dong-feng, HUANG Hai-hong. Recent advances in study of drugs against Gram-negative pathogensJ. Acta Pharmaceutica Sinica, 2019,54(9): 1554-1563. doi: 10.16438/j.0513-4870.2019-0467
Citation: LU Hai-jia, ZHANG Dong-feng, HUANG Hai-hong. Recent advances in study of drugs against Gram-negative pathogensJ. Acta Pharmaceutica Sinica, 2019,54(9): 1554-1563. doi: 10.16438/j.0513-4870.2019-0467

抗革兰氏阴性菌药物的研究进展

Recent advances in study of drugs against Gram-negative pathogens

  • 摘要: 抗生素在临床上的长期使用导致细菌发生变异和耐药,另外,抗生素在医疗及农业领域的过度使用或不当使用加剧细菌耐药性的发生。2017年世界卫生组织首次公布了最需要新抗生素的12种细菌和细菌家族清单,其中9种为革兰氏阴性菌。革兰氏阴性菌具有多层结构的细胞壁,这种特殊的结构导致许多抗生素不能通过革兰氏阴性菌的外膜到达靶点,因此,抗革兰氏阴性菌的药物研发难度巨大,过去50年来,还没有针对革兰氏阴性菌的新机制抗生素获得批准。本文简要综述了目前不同作用机制下抗革兰氏阴性菌药物的研究进展。

     

    Abstract: The long-term use of antibiotics in clinical practice leads to bacterial variation and resistance. In addition, the excessive or improper use of antibiotics in medical and agricultural fields increases the occurrence of bacterial resistance. In 2017, the World Health Organization has for the first time released a list of 12 bacteria or bacterial families that pose the greatest threat to human health and for which new antibiotics are desperately needed, and three quarters of them are Gram-negative bacteria. Gram-negative bacteria has multi-layered cell wall that prevents many antibiotics from accessing their targets. Therefore, it is very difficult to develop drugs against Gram-negative bacteria, no new class of antibiotic has been approved for Gram-negative pathogens in over fifty years. Here, we summarized recent advances in the study of new antibacterial agents with different mechanisms of action against Gram-negative pathogens.

     

/

返回文章
返回